# A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

> **NCT02978235** · PHASE1 · TERMINATED · sponsor: **Taiho Oncology, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Multiple Myeloma
- NonHodgkin Lymphoma

## Interventions

- **DRUG:** TAS4464

## Key facts

- **NCT ID:** NCT02978235
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-01
- **Primary completion:** 2018-02-01
- **Final completion:** 2018-02-01
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The trial was put on Clinical Hold and subsequently terminated prior to Phase 2 due to cases of drug induced liver injury meeting the criteria for Hy's Law
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02978235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02978235, "A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02978235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*